Adjuvant chemotherapy for osteogenic sarcoma of the extremity with sequential adriamycin and cisplatin

J Surg Oncol. 1993 Mar;52(3):181-4. doi: 10.1002/jso.2930520313.

Abstract

Twenty-nine patients with high-grade nonmetastatic osteogenic sarcoma of the extremities were treated with adjuvant chemotherapy following definitive surgery. Chemotherapy consisted of systemic intravenous Adriamycin and cisplatin in a sequential fashion given for six courses. Nineteen out of 29 patients are alive and continuously disease free over a follow-up period ranging from 9+ to 30+ months. The relapse-free survival was 72%, and overall survival for the entire group was 69%. Median survival is not reached yet. Six out of 29 patients relapsed, of which 1 patient is alive for 6+ months after relapse. Three patients died of chemotherapy toxicity. The results were superior to historical controls treated with surgery alone. The need for more aggressive treatment approaches is discussed.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Arm*
  • Bone Neoplasms / drug therapy*
  • Chemotherapy, Adjuvant
  • Child
  • Cisplatin / administration & dosage
  • Doxorubicin / administration & dosage
  • Drug Administration Schedule
  • Female
  • Humans
  • Infusions, Intravenous
  • Leg*
  • Male
  • Osteosarcoma / drug therapy*
  • Survival Analysis

Substances

  • Doxorubicin
  • Cisplatin